JUN 18, 2015 3:39 PM PDT

Paving the Way to Earlier Prostate Cancer Diagnosis

WRITTEN BY: Ilene Schneider
According to the National Cancer Institute, prostate cancer is the most common cancer in men in the United States, after skin cancer, and the second leading cause of death from cancer in men. Occurring more often in African-American men than in white men, prostate cancer claims the lives of more African-American men than white men. Nearly all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Prostate cancer, which often has no early symptoms, usually grows very slowly. Most men who have prostate cancer are older than 65 years and usually die from something other than the disease (http://www.cancer.gov/types/prostate).
Researchers want to make DNA-based prostate cancer screening as readily available as breast cancer screening.
Now scientists at UC San Francisco and Kaiser Permanente Northern California believe that they can achieve earlier diagnosis of the disease by screening men with an elevated, genetically inherited risk for prostate cancer using a simple blood or urine test. The study, which compared 7,783 men with prostate cancer to 38,595 without the disease, was reported in Science Daily and will be published in Cancer Discovery (Pete Farley, University of California, San Francisco (UCSF). "Tests to gauge genetic risks for prostate cancer now are feasible." ScienceDaily. ScienceDaily, 17 June 2015) (www.sciencedaily.com/releases/2015/06/150617162032.htm).

According to the Science Daily article, "The new study is one of the first to come out of the collaboration between UCSF and Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH), which analyzed genetic samples and health records from more than 100,000 volunteers, making it one of the largest research projects in the United States to examine the genetic, health and environmental factors that influence common diseases such as prostate cancer."

Using 105 specific bits of DNA that commonly vary among individuals and are associated with prostate cancer risk, the researchers concluded that men with combinations of these DNA variants that placed them at high risk were more than six times as likely to be diagnosed with prostate cancer as compared with the men who ranked at low risk. Researchers said that men who were in the highest percentiles for risk in the study have a prostate cancer risk comparable to the breast cancer risk among women who carry a mutation in one of the so-called breast cancer genes, BRCA1 or BRCA2. Although women suspected of having mutated BRCA genes can undergo commercially available genetic testing, there is no comparable clinical test to measure genetic risk for prostate cancer.

As John Witte, PhD, a UCSF professor of epidemiology and biostatistics and of urology, who led the study along with Stephen Van Den Eeden, PhD, at Kaiser Permanente, "We developed a risk model that may have clinical value. We also showed that there remain substantial undiscovered genetic risk factors for prostate cancer."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAR 10, 2020
Cancer
MAR 10, 2020
Chemo more effective with Intralipid treatment
A study published recently in Scientific Reports suggests a novel technique to make chemotherapy more effective. Th ...
MAR 29, 2020
Cancer
MAR 29, 2020
Improving ependymoma diagnostics
Have you ever heard of ependymoma? This rare form of brain cancer most commonly occurs in young children when tumors for ...
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
APR 07, 2020
Cancer
APR 07, 2020
Chemo drugs are leaking into our water
With cancer as the second leading cause of death globally, it comes as a surprise that we know very little up until now ...
MAY 16, 2020
Cancer
MAY 16, 2020
Red Blood Cells: More than just an Oxygen Delivery Service
The human body is a complex network of systems that often interact and affect each other. Recent work shows that red blo ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
Loading Comments...